DOCSLIB.ORG

Supplementary Tables

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Tables Bastian et al. 2012 SUPPLEMENTARY TABLES Synergistic activity of bortezomib and HDACis in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT and NF-B Lorenz Bastian, Jana Hof, Madlen Pfau, Iduna Fichtner, Cornelia Eckert, Günter Henze, Javier Prada, Arend von Stackelberg, Karl Seeger and Shabnam Shalapour 0 Bastian et al. 2012 Supplementary Table S1. Fractional Product of Webb calculations for concomitant combinations of HDACis (VPA, SAHA) and bortezomib or chemotherapeutic agents in Nalm6 cells. VPA SAHA bortezomib 6 nM 2.73 3.47 8 nM 1.23 1.27 idarubicin 10 nM 1.56 1.51 20 nM 1.19 1.22 cytarabine 20 nM 1.53 1.29 80 nM 0.85 0.83 vincristine 3 nM 1.53 1.89 5 nM 0.90 0.99 Nalm6 cells were treated for 72 h with either BTZ or chemotherapeutic agents alone or in combination with HDACis (VPA, SAHA). BTZ and chemotherapeutics were applied at moderate and submaximal effective dose levels as indicated. Apoptosis was assessed by FACS analysis of annexin-V/PI stained cells. Results are shown in Supplementary Figure S2A. Fractional product method of Webb relates a measured effect of combined treatment to an expected effect calculated from the effects of treatment with single drugs. Values <1 indicate antagonism, ~ 1 indicate additivity, > 1 indicate synergism. Abbreviations: VPA, valproic acid; SAHA, suberoylanilide hydroxamic acid. 1 Bastian et al. 2012 Supplementary Table S2. Sensitivities of Reh, Nalm6 and 697 cells to treatments with VPA and SAHA. VPA (mM) SAHA (μM) Reh Ic25 3.6 1.3 Ic50 > 6 > 2.4 Nalm6 Ic25 2.1 1.6 Ic50 > 3 2.2 697 Ic25 1.5 0.9 Ic50 2.1 1.1 Cell lines were treated with serial dilutions of VPA or SAHA. After 72 h apoptosis was measured by FACS analysis of annexin-V / PI stained cells, as indicated in Supplementary Figure S1B-D. The 25% and 50% effective concentrations were determined by linear regression analysis. 2 Bastian et al. 2012 Supplementary Table S3. Fractional Product of Webb calculations for concomitant combinations of BTZ and VPA in 697, SD-1 and SEM cells at three different time points. VPA (24 h) VPA (48 h) VPA (72 h) 697 BTZ (10 nM) 4.21 5.34 12.36 BTZ (14 nM) 2.74 2.86 4.30 SD-1 BTZ (10 nM) 1.67 2.54 36.91 BTZ (12 nM) 1.12 1.01 1.19 SEM BTZ (2 nM) 1.20 1.51 1.60 BTZ (4 nM) 1.61 1.31 1.20 697, SD-1 and SEM cells were exposed to BTZ at two concentrations, combined concomitantly with or without VPA. After 24 h, 48 h and 72 h of treatment, cytotoxicity was assessed by FACS analysis of PI stained cells. The IC 50 concentrations determined for BTZ single treatments after 48h were 18.2 nM, 10.5 nM and 4.0 nM for 697, SD-1 and SEM respectively. Fractional product method of Webb relates a measured effect of combined treatment to an expected effect calculated from the effects of treatment with single drugs. Values <1 indicate antagonism, ~ 1 indicate additivity, > 1 indicate synergism. Abbreviations: BTZ, bortezomib. VPA, valproic acid. 3 Bastian et al. 2012 Supplementary Table S4. Fractional Product of Webb calculations for concomitant and sequential combinations of BTZ and HDACis (VPA, SAHA) in Reh and Nalm6 cells. BTZ + HDACi BTZ + HDACi BTZ b HDACi HDACi b BTZ HDACi (36 h) (72 h) Reh VPA 5.36 5.82 1.28 0.30 SAHA 4.94 4.44 1.12 0.88 Nalm6 VPA n.d. 3.79 0.89 0.59 SAHA n.d. 3.17 1.31 0.99 Reh and Nalm6 cells were treated with BTZ for 36 h, washed and resuspended in fresh media containing HDACis (VPA, SAHA) for further 36 h or the reversed order of drug application. As controls were used: treatments with single drugs for 36 h, after which cells were washed and resuspended in fresh media without drugs for further 36 h or treatments with the combination of HDACI/BTZ for 36 h, after which cells were washed and resuspended again for further 36 h in media containing the HDACI/BTZ combination. After 72 h cells were stained with Annexin-V/PI and the proportions of apoptotic cells were determined by FACS. Apoptosis rates in Reh cells after 36 h of treatment with VPA/BTZ and SAHA/BTZ were 89.8% (±0.4) and 72.9% (± 3.6) respectively. Representative results are shown in Figure 1C. Fractional product method of Webb relates a measured effect of combined treatment to an expected effect calculated from the effects of treatment with single drugs. Values <1 indicate antagonism, ~ 1 indicate additivity, > 1 indicate synergism. Abbreviations: BTZ, bortezomib; VPA, valproic acid; SAHA, suberoylanilide hydroxamic acid; n.d. not determined. 4 Bastian et al. 2012 Supplementary Table S5. NF-B subunits gene expression in leukemia cells in correlation with the clinical and biological characteristics of the BCP-ALL relapse patient cohort. Parameter Total RelA RelB NFKB2 NFKB1 Total N median (min;max) p-value median (min;max) p-value median (min;max) p-value median (min;max) p-value gender 0.16 0.36 0.24 0.25 male 36 8.25(7.40; 8.97) 7.57(6.39;9.4) 7.42(6.66;8.50) 9(8.25;10.61) female 16 8.18 (7.56;8.56) 7.37(6.17;8.75) 7.05(6.51;8.81) 8.75(7.64;10.61) age at relapse 0.80 0.28 0.38 0.09 < 5 years 7 8.34(7.84;8.62) 7.79(6.88;8.75) 7.03(6.86;8.50) 8.63(8.35;9.62) 5 and < 10 years 22 8.12(7.40;8.96) 7.6(6.17;9.4) 7.49(6.61;8.81) 9.2(8.43;10.61) 10 years 23 8.27(7.56;8.97) 7.33(6.57;8.32) 7.24(6.51;8.40) 8.97(7.64;9.99) timepoint of relapse 0.03 0.05 0.03 0.05 very early 14 8.15(7.46;8.55) 7.22(6.57;8.42) 6.9(6.6;8.5) 8.75(8.25;9.62) early 10 8.05(7.40;8.62) 7.46(6.39;8.4) 7.25(6.81;8.45) 8.87(7.64;10.69) late 28 8.35(7.56;8.97) 7.65(6.17;9.4) 7.5(6.51;8.81) 9.12(8.35;10.61) relapse on/off initial treatment 0.006 0.01 0.008 0.03 on treatment 18 8.05(7.46;8.62) 7.22(6.57;8.42) 7.02(6.60;8.50) 8.82(7.64;10.59) off treatment 34 8.35(7.40;8.97) 7.65(6.17;9.4) 7.5(6.51;8.81) 9.08(8.35;10.61) site of relapse 0.24 0.19 0.19 0.43 BM isolated 45 8.21(7.40;8.96) 7.44(6.17;9.4) 7.26(6.51;8.81) 8.96(7.64;10.61) BM combined 7 8.36(7.99;8.97) 7.88(7.43;8.4) 7.44(7.07;8.49) 9.11(8.76;9.89) immunophenotype 0.60 0.18 0.35 0.57 Pro–B-cell ALL 4 8.44(7.93;8.69) 7.85(7.58;8.4) 7.53(6.97;8.49) 9.71(8.35;9.89) Common ALL 29 8.17(7.46;8.97) 7.44(6.17;9.4) 7.14(6.51;8.48) 8.9(7.64;10.61) Pre-B-cell ALL 15 8.3(7.40;8.84) 7.43(6.39;8.59) 7.43(6.74;8.81) 9.01(8.25;10.61) BCP-ALL not specified 4 response to treatment 0.44 0.22 0.04 0.86 early/normal 31 8.27(7.40;8.97) 7.58(6.17;9.4) 7.53(6.51;8.81) 8.93(8.25;10.61) late/non-response 18 8.18(7.76;8.61) 7.33(6.7;8.9) 7.05(6.61;8.48) 8.99(7.64;10.69) (no data) 3 Outcome 0.63 0.59 0.48 0.23 CCR 13 8.16(7.40;8.97) 7.9(6.17;9.4) 7.26(6.51;8.47) 8.81(8.4;9.96) death in CR 3 8.61(8.07;8.72) 7.01(6.9;7.37) 7.05(6.74;7.77) 8.82(8.59;9.06) second relapse 24 8.32(7.46;8.94) 7.62(6.57;8.59) 7.5(6.61;8.81) 9.12(7.64;10.61) non-response 7 8.27(7.85;8.42) 7.42(6.7;8.9) 7.24(6.9;8.48) 9.17(8.38;9.77) induction death 1 7.93(-;-) 7.12(-;-) 6.6(-;-) 8.37(-;-) (non protocol) 4 second event 0.67 0.79 0.70 0.20 no 13 8.16(7.40;8.97) 7.9(6.17;9.4) 7.26(6.51;8.47) 8.81(8.4;9.96) yes 35 8.31(7.46;8.94) 7.48(6.57;8.9) 7.4(6.6;8.81) 9.06(7.64;10.61) (non protocol) 4 Abbreviations: BCP, B-cell precursor; ALL, acute lymphoblastic leukemia; BM, bone marrow; CR, complete remission; CCR, continuous complete remission.
Load more

Recommended publications
  • IDENTIFICATION of CELL SURFACE MARKERS WHICH CORRELATE with SALL4 in a B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA with T(8;14)
    IDENTIFICATION of CELL SURFACE MARKERS WHICH CORRELATE WITH SALL4 in a B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(8;14) DISCOVERED THROUGH BIOINFORMATIC ANALYSIS of MICROARRAY GENE EXPRESSION DATA The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:38962442 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA ,'(17,),&$7,21 2) &(// 685)$&( 0$5.(56 :+,&+ &255(/$7( :,7+ 6$// ,1 $ %&(// $&87( /<03+2%/$67,& /(8.(0,$ :,7+ W ',6&29(5(' 7+528*+ %,2,1)250$7,& $1$/<6,6 2) 0,&52$55$< *(1( (;35(66,21 '$7$ 52%(57 3$8/ :(,1%(5* $ 7KHVLV 6XEPLWWHG WR WKH )DFXOW\ RI 7KH +DUYDUG 0HGLFDO 6FKRRO LQ 3DUWLDO )XOILOOPHQW RI WKH 5HTXLUHPHQWV IRU WKH 'HJUHH RI 0DVWHU RI 0HGLFDO 6FLHQFHV LQ ,PPXQRORJ\ +DUYDUG 8QLYHUVLW\ %RVWRQ 0DVVDFKXVHWWV -XQH Thesis Advisor: Dr. Li Chai Author: Robert Paul Weinberg Department of Pathology Candidate MMSc in Immunology Brigham and Womens’ Hospital Harvard Medical School 77 Francis Street 25 Shattuck Street Boston, MA 02215 Boston, MA 02215 IDENTIFICATION OF CELL SURFACE MARKERS WHICH CORRELATE WITH SALL4 IN A B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH TRANSLOCATION t(8;14) DISCOVERED THROUGH BIOINFORMATICS ANALYSIS OF MICROARRAY GENE EXPRESSION DATA Abstract Acute Lymphoblastic Leukemia (ALL) is the most common leukemia in children, causing signficant morbidity and mortality annually in the U.S.
    [Show full text]
  • Cytoplasmic Activation-Induced Cytidine Deaminase (AID) Exists in Stoichiometric Complex with Translation Elongation Factor 1Α (Eef1a)
    Cytoplasmic activation-induced cytidine deaminase (AID) exists in stoichiometric complex with translation elongation factor 1α (eEF1A) Julien Häsler, Cristina Rada, and Michael S. Neuberger1 Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom Edited by Frederick W. Alt, Howard Hughes Medical Institute, Harvard Medical School, Children’s Hospital Immune Disease Institute, Boston, MA, and approved October 12, 2011 (received for review April 27, 2011) Activation-induced cytidine deaminase (AID) is a B lymphocyte- results reveal that endogenous cytoplasmic AID partakes in a specific DNA deaminase that acts on the Ig loci to trigger antibody complex containing stoichiometric quantities of translation elon- gene diversification. Most AID, however, is retained in the cyto- gation factor 1α (eEF1A), with this association likely implicated in plasm and its nuclear abundance is carefully regulated because the regulation of AID’s intracellular trafficking. off-target action of AID leads to cancer. The nature of the cytosolic AID complex and the mechanisms regulating its release from the Results cytoplasm and import into the nucleus remain unknown. Here, we Flag-Tagging the Endogenous AID Locus in DT40 Cells. We generated show that cytosolic AID in DT40 B cells is part of an 11S complex derivatives of the DT40 B-cell line in which the endogenous AID and, using an endogenously tagged AID protein to avoid overex- locus was modified so as to incorporate a single Flag tag at the pression artifacts, that it is bound in good stoichiometry to the AID N terminus. To allow targeting of both alleles, one targeting translation elongation factor 1 alpha (eEF1A).
    [Show full text]
  • Supplement 1 Overview of Dystonia Genes
    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
    [Show full text]
  • PDF Datasheet
    Product Datasheet C9orf85 Overexpression Lysate NBL1-08604 Unit Size: 0.1 mg Store at -80C. Avoid freeze-thaw cycles. Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBL1-08604 Updated 3/17/2020 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBL1-08604 Page 1 of 2 v.20.1 Updated 3/17/2020 NBL1-08604 C9orf85 Overexpression Lysate Product Information Unit Size 0.1 mg Concentration The exact concentration of the protein of interest cannot be determined for overexpression lysates. Please contact technical support for more information. Storage Store at -80C. Avoid freeze-thaw cycles. Buffer RIPA buffer Target Molecular Weight 18.1 kDa Product Description Description Transient overexpression lysate of chromosome 9 open reading frame 85 (C9orf85) The lysate was created in HEK293T cells, using Plasmid ID RC208807 and based on accession number NM_182505. The protein contains a C- MYC/DDK Tag. Gene ID 138241 Gene Symbol C9ORF85 Species Human Notes HEK293T cells in 10-cm dishes were transiently transfected with a non-lipid polymer transfection reagent specially designed and manufactured for large volume DNA transfection. Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer (25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 1mM EDTA, 1xProteinase inhibitor cocktail mix, 1mM PMSF and 1mM Na3VO4, and then centrifuged to clarify the lysate. Protein concentration was measured by BCA protein assay kit.This product is manufactured by and sold under license from OriGene Technologies and its use is limited solely for research purposes.
    [Show full text]
  • Examination of the Transcription Factors Acting in Bone Marrow
    THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PHD) Examination of the transcription factors acting in bone marrow derived macrophages by Gergely Nagy Supervisor: Dr. Endre Barta UNIVERSITY OF DEBRECEN DOCTORAL SCHOOL OF MOLECULAR CELL AND IMMUNE BIOLOGY DEBRECEN, 2016 Table of contents Table of contents ........................................................................................................................ 2 1. Introduction ............................................................................................................................ 5 1.1. Transcriptional regulation ................................................................................................... 5 1.1.1. Transcriptional initiation .................................................................................................. 5 1.1.2. Co-regulators and histone modifications .......................................................................... 8 1.2. Promoter and enhancer sequences guiding transcription factors ...................................... 11 1.2.1. General transcription factors .......................................................................................... 11 1.2.2. The ETS superfamily ..................................................................................................... 17 1.2.3. The AP-1 and CREB proteins ........................................................................................ 20 1.2.4. Other promoter specific transcription factor families ...................................................
    [Show full text]
  • Dual Proteome-Scale Networks Reveal Cell-Specific Remodeling of the Human Interactome
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dual Proteome-scale Networks Reveal Cell-specific Remodeling of the Human Interactome Edward L. Huttlin1*, Raphael J. Bruckner1,3, Jose Navarrete-Perea1, Joe R. Cannon1,4, Kurt Baltier1,5, Fana Gebreab1, Melanie P. Gygi1, Alexandra Thornock1, Gabriela Zarraga1,6, Stanley Tam1,7, John Szpyt1, Alexandra Panov1, Hannah Parzen1,8, Sipei Fu1, Arvene Golbazi1, Eila Maenpaa1, Keegan Stricker1, Sanjukta Guha Thakurta1, Ramin Rad1, Joshua Pan2, David P. Nusinow1, Joao A. Paulo1, Devin K. Schweppe1, Laura Pontano Vaites1, J. Wade Harper1*, Steven P. Gygi1*# 1Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA. 2Broad Institute, Cambridge, MA, 02142, USA. 3Present address: ICCB-Longwood Screening Facility, Harvard Medical School, Boston, MA, 02115, USA. 4Present address: Merck, West Point, PA, 19486, USA. 5Present address: IQ Proteomics, Cambridge, MA, 02139, USA. 6Present address: Vor Biopharma, Cambridge, MA, 02142, USA. 7Present address: Rubius Therapeutics, Cambridge, MA, 02139, USA. 8Present address: RPS North America, South Kingstown, RI, 02879, USA. *Correspondence: [email protected] (E.L.H.), [email protected] (J.W.H.), [email protected] (S.P.G.) #Lead Contact: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • A CRISPR-Cas9–Engineered Mouse Model for GPI-Anchor Deficiency Mirrors Human Phenotypes and Exhibits Hippocampal Synaptic Dysfunctions
    A CRISPR-Cas9–engineered mouse model for GPI-anchor deficiency mirrors human phenotypes and exhibits hippocampal synaptic dysfunctions Miguel Rodríguez de los Santosa,b,c,d, Marion Rivalane,f, Friederike S. Davidd,g, Alexander Stumpfh, Julika Pitschi,j, Despina Tsortouktzidisi, Laura Moreno Velasquezh, Anne Voigth, Karl Schillingk, Daniele Matteil, Melissa Longe,f, Guido Vogta,c, Alexej Knausd, Björn Fischer-Zirnsaka,c, Lars Wittlerm, Bernd Timmermannn, Peter N. Robinsono,p, Denise Horna, Stefan Mundlosa,c, Uwe Kornaka,c,q, Albert J. Beckeri, Dietmar Schmitzh, York Wintere,f, and Peter M. Krawitzd,1 aInstitute for Medical Genetics and Human Genetics, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany; bBerlin-Brandenburg School for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; cResearch Group Development and Disease, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany; dInstitute for Genomic Statistics and Bioinformatics, University of Bonn, 53127 Bonn, Germany; eAnimal Outcome Core Facility of the NeuroCure Center, Charité–Universitätsmedizin Berlin, 10117 Berlin, Germany; fInstitute of Cognitive Neurobiology, Humboldt University, 10117 Berlin, Germany; gInstitute of Human Genetics, Faculty of Medicine, University Hospital Bonn, 53127 Bonn, Germany; hNeuroscience Research Center, Charité–Universitätsmedizin Berlin, 10117 Berlin, Germany; iSection for Translational Epilepsy Research, Department of Neuropathology, University Hospital Bonn, 53127 Bonn, Germany; jDepartment of Epileptology,
    [Show full text]
  • Functional Genomics Atlas of Synovial Fibroblasts Defining Rheumatoid Arthritis
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability Xiangyu Ge1*, Mojca Frank-Bertoncelj2*, Kerstin Klein2, Amanda Mcgovern1, Tadeja Kuret2,3, Miranda Houtman2, Blaž Burja2,3, Raphael Micheroli2, Miriam Marks4, Andrew Filer5,6, Christopher D. Buckley5,6,7, Gisela Orozco1, Oliver Distler2, Andrew P Morris1, Paul Martin1, Stephen Eyre1* & Caroline Ospelt2*,# 1Versus Arthritis Centre for Genetics and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK 2Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 3Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia 4Schulthess Klinik, Zurich, Switzerland 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK 6NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK 7Kennedy Institute of Rheumatology, University of Oxford Roosevelt Drive Headington Oxford UK *These authors contributed equally #corresponding author: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Sexual Dimorphism in Brain Transcriptomes of Amami Spiny Rats (Tokudaia Osimensis): a Rodent Species Where Males Lack the Y Chromosome Madison T
    Ortega et al. BMC Genomics (2019) 20:87 https://doi.org/10.1186/s12864-019-5426-6 RESEARCHARTICLE Open Access Sexual dimorphism in brain transcriptomes of Amami spiny rats (Tokudaia osimensis): a rodent species where males lack the Y chromosome Madison T. Ortega1,2, Nathan J. Bivens3, Takamichi Jogahara4, Asato Kuroiwa5, Scott A. Givan1,6,7,8 and Cheryl S. Rosenfeld1,2,8,9* Abstract Background: Brain sexual differentiation is sculpted by precise coordination of steroid hormones during development. Programming of several brain regions in males depends upon aromatase conversion of testosterone to estrogen. However, it is not clear the direct contribution that Y chromosome associated genes, especially sex- determining region Y (Sry), might exert on brain sexual differentiation in therian mammals. Two species of spiny rats: Amami spiny rat (Tokudaia osimensis) and Tokunoshima spiny rat (T. tokunoshimensis) lack a Y chromosome/Sry, and these individuals possess an XO chromosome system in both sexes. Both Tokudaia species are highly endangered. To assess the neural transcriptome profile in male and female Amami spiny rats, RNA was isolated from brain samples of adult male and female spiny rats that had died accidentally and used for RNAseq analyses. Results: RNAseq analyses confirmed that several genes and individual transcripts were differentially expressed between males and females. In males, seminal vesicle secretory protein 5 (Svs5) and cytochrome P450 1B1 (Cyp1b1) genes were significantly elevated compared to females, whereas serine (or cysteine) peptidase inhibitor, clade A, member 3 N (Serpina3n) was upregulated in females. Many individual transcripts elevated in males included those encoding for zinc finger proteins, e.g.
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]
  • Phenotypic Spectrum and Long-Term Outcome in Children with Genetic Causes of Early-Onset Epileptic Encephalopathy
    Phenotypic Spectrum and Long-term Outcome in Children With Genetic Causes of Early-onset Epileptic Encephalopathy Chunhui Hu Department of Neurology, Children’s Hospital of Fudan University Deying Liu Wuhan Children’s hospital, Tongji Medical college, Huazhong University of Science & Technology Tian Luo Department of Neurology, Children’s Hospital of Fudan University Yi Wang ( [email protected] ) Department of Neurology, Children’s Hospital of Fudan University Zhisheng Liu Wuhan Children’s hospital, Tongji Medical college, Huazhong University of Science & Technology Research Article Keywords: Phenotypic spectrum, Long-term outcome, Genetic, EOEE, Therapy Posted Date: March 11th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-257334/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/23 Abstract Background To explore the clinical phenotype and long-term outcome in children with genetic causes of early-onset epileptic encephalopathies. Methods The clinical data of 118 children between 2010 and 2020 was obtained and analyzed. The whole exome sequencing and copy number variation studies in family were used to nd pathogenic mutations. The conrmed mutations were veried by Sanger sequencing. Results Among 118 patients, 39 patients were diagnosed with DS, 18 were WS, 3 were OS, 3 were EME, 2 were MMFSI, 1 was GLUT1 deciency syndrome, 1 was Pyridoxine dependent epilepsy and 51 were non-symptomatic EOEEs. The initial EEG showed frequent multiple and multifocal sharp waves, spike waves, sharp slow waves or spike slow waves. In the later period, some transformed into infrequent discharging or normal EEG. 112 patients (112/118, 94.9%) showed normal brain MRI, and the remaining 6 had widened extracerebral space.
    [Show full text]